Futile Immunotherapy for Cancer Grows More Common | MedPage Today
… cancer (NSCLC), and 0.5% to 2.6% for kidney cell carcinoma. By 2019, these end-of-life–initiated treatments represented 7.3% of all immunotherapy …
… cancer (NSCLC), and 0.5% to 2.6% for kidney cell carcinoma. By 2019, these end-of-life–initiated treatments represented 7.3% of all immunotherapy …
